Gino Roberto Corazza

Gino Roberto Corazza

Auto-generated profile, based on publicly available information

Gino Roberto Corazza

Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Autoimmunity Reviews
Verified
Journal Article
Closed access
AGAlessandra Geremia
Alessandra Geremia
PBPaolo Biancheri
Paolo Biancheri
PAPhilip Allan
Philip Allan
GCGino R. Corazza
Gino R. Corazza
ASAntonio Di Sabatino
Antonio Di Sabatino

1 July 2011 in The Lancet
Verified
Journal Article
Closed access
ASAntonio Di Sabatino
Antonio Di Sabatino
RCRita Carsetti
Rita Carsetti
GCGino Roberto Corazza
Gino Roberto Corazza

1 April 2009 in The Lancet
Verified
Journal Article
Closed access
ASAntonio Di Sabatino
Antonio Di Sabatino
GCGino Roberto Corazza
Gino Roberto Corazza

21 January 2011 in Gut
Verified
Journal Article
Closed access
PDF file
RCRachele Ciccocioppo
Rachele Ciccocioppo
MBMaria Ester Bernardo
Maria Ester Bernardo
ASAdele Sgarella
Adele Sgarella
RMRita Maccario
Rita Maccario
SCStefania Croce
Stefania Croce
GCGino Roberto Corazza
Gino Roberto Corazza
Objective: External fistulas represent a disabling manifestation of Crohn's disease with a difficult curability and a high relapse rate despite a large therapeutic armamentarium. Stem cell therapy is a novel and promising approach for treatment of chronic inflammatory conditions. We therefore investigated the feasibility, safety and efficacy of serial intrafistular injections of autologous bone marrow-derived mesenchymal stromal cells (MSCs) in the treatment of fistulising Crohn's disease. Patients and methods: We enrolled 12 consecutive outpatients (eight males, median age 32 years) refractory to or unsuitable for current available therapies. MSCs were isolated from bone marrow and expanded ex vivo to be used for both therapeutic and experimental purposes. Ten patients (two refused) received intrafistular MSC injections (median 4) scheduled every 4 weeks, and were monitored by surgical, MRI and endoscopic evaluation for 12 months afterwards. The feasibility of obtaining at least 50×10 6 MSCs from each patient, the appearance of adverse events, and the efficacy in terms of fistula healing and reduction of both Crohn's disease and perianal disease activity indexes were evaluated. In addition, the percentage of both mucosal and circulating regulatory T cells expressing FoxP3, and the ability of MSCs to influence mucosal T cell apoptosis were investigated. Results: MSC expansion was successful in all cases; sustained complete closure (seven cases) or incomplete closure (three cases) of fistula tracks with a parallel reduction of Crohn's disease and perianal disease activity indexes (p<0.01 for both), and rectal mucosal healing were induced by treatment without any adverse effects. The percentage of mucosal and circulating regulatory T cells significantly increased during the treatment and remained stable until the end of follow up (p<0.0001 and p<0.01, respectively). Furthermore, MSCs have been proven to affect mucosal T cell apoptotic rate. Conclusions: Locally injected MSCs represent a feasible, safe and beneficial therapy in refractory fistulising Crohn's disease.

1 August 2001 in The Lancet
Verified
Journal Article
Closed access
GCGiovanni Corrao
Giovanni Corrao
GCGino Roberto Corazza
Gino Roberto Corazza
VBVincenzo Bagnardi
Vincenzo Bagnardi
GBGiovanna Brusco
Giovanna Brusco
Carolina CiacciCarolina Ciacci
Carolina Ciacci
MCMaria Certo
Maria Certo

19 March 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GMGiovanni Monteleone
Giovanni Monteleone
MNMarkus F. Neurath
Markus F. Neurath
SASandro Ardizzone
Sandro Ardizzone
ASAntonio Di Sabatino
Antonio Di Sabatino
MFMassimo C. Fantini
Massimo C. Fantini
FPFrancesco Pallone
Francesco Pallone
Crohn’s disease–related inflammation is characterized by reduced activity of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels of SMAD7, an inhibitor of TGF-β1 signaling. Preclinical studies and a phase 1 study have shown that an oral SMAD7 antisense oligonucleotide, mongersen, targets ileal and colonic SMAD7. In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of mongersen for the treatment of persons with active Crohn’s disease. Patients were randomly assigned to receive 10, 40, or 160 mg of mongersen or placebo per day for 2 weeks. The primary outcomes were clinical remission at day 15, defined as a Crohn’s Disease Activity Index (CDAI) score of less than 150, with maintenance of remission for at least 2 weeks, and the safety of mongersen treatment. A secondary outcome was clinical response (defined as a reduction of 100 points or more in the CDAI score) at day 28. The proportions of patients who reached the primary end point were 55% and 65% for the 40-mg and 160-mg mongersen groups, respectively, as compared with 10% for the placebo group (P<0.001). There was no significant difference in the percentage of participants reaching clinical remission between the 10-mg group (12%) and the placebo group. The rate of clinical response was significantly greater among patients receiving 10 mg (37%), 40 mg (58%), or 160 mg (72%) of mongersen than among those receiving placebo (17%) (P=0.04, P<0.001, and P<0.001, respectively). Most adverse events were related to complications and symptoms of Crohn’s disease. We found that study participants with Crohn’s disease who received mongersen had significantly higher rates of remission and clinical response than those who received placebo. (Funded by Giuliani; EudraCT number, 2011-002640-27.)